Resistance mutation info of drug
Drug General Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug ID | D0K0YC | ||||||||||
Drug Name | PD-0325901 | ||||||||||
Synonyms | PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide | ||||||||||
Drug Type | Small molecular drug | ||||||||||
Therapeutic Class | Anticancer Agents | ||||||||||
Company | Pfizer | ||||||||||
Structure | |||||||||||
Drug Resistance Mutations | |||||||||||
Target Name | Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) | Target Info | |||||||||
Gene Name | MAP2K2 | ||||||||||
Uniprot ID | MP2K2_HUMAN | ||||||||||
Species | Homo sapiens | ||||||||||
Reference Sequence |
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV [Homo sapiens] |
||||||||||
Targeted Disease | Lung cancer | ||||||||||
Drug Resistance Mutations |
|
||||||||||
Target Name | Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) | Target Info | |||||||||
Gene Name | MAP2K1 | ||||||||||
Uniprot ID | MP2K1_HUMAN | ||||||||||
Species | Homo sapiens | ||||||||||
Reference Sequence |
MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKV GELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHE CNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYL REKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHY SVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSY GMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAF IKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV [Homo sapiens] |
||||||||||
Targeted Disease | Lung cancer | ||||||||||
Drug Resistance Mutations |
|
||||||||||
|
|||||||||||
References | |||||||||||
REF 1 | ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012 May;11(5):1143-54. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.